Bristol Myers Squibb

Bristol Myers Squibb(CELG-RI)

PRINCETON, NJ
Pharmaceutical1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Biologics

Bristol Myers Squibb is a life sciences company focused on Small Molecules, Biologics.

OncologyHematologyImmunologyCardiovascularNeuroscience
Funding Stage
PUBLIC
Employees
34,300
Open Jobs
731

Products & Portfolio (6)

44 discontinued products not shown

ABRAXANE
paclitaxel
Peak
INTRAVENOUS · POWDER
depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
breast cancer after failure of combination chemotherapy for metastatic diseaserelapse within 6 months of adjuvant chemotherapybreast cancer+1 more
2005
0
AUGTYRO
repotrectinib
Growth
SMORAL · CAPSULE
Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors
• are locally advancedmetastaticwhere surgical resection is likely to result in severe morbidity+2 more
2023
0
AZACTAM
aztreonam
LOE Approaching
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Single 30-minute intravenous infusions of 500 mg, 1 g, and 2 g doses of AZACTAM in healthy subjects produced aztreonam peak serum levels of 54 mcg/mL, 90 mcg/mL, and 204 mcg/mL, respectively, immediately after administration; at 8 hours, serum levels were 1 mcg/mL, 3 mcg/mL, and 6 mcg/mL, respectively (Figure 1). Single 3-minute intravenous injections of the same doses resulted in serum levels of 58 mcg/mL, 125 mcg/mL, and 242 mcg/mL at 5 minutes following completion of injection. Serum concentrations of aztreonam in healthy subjects following completion of single intramuscular injections of 500 mg and 1 g doses are depicted in Figure 1; maximum serum concentrations occur at about 1 hour. After identical single intravenous or intramuscular doses of AZACTAM, the serum concentrations of aztreonam are comparable at 1 hour (1.5 hours from start of intravenous infusion) with similar slopes of serum concentrations thereafter. FIGURE 1 The serum levels of aztreonam following single 500 mg or 1 g (intramuscular or intravenous) or 2 g (intravenous) doses of AZACTAM exceed the MIC 90 for Neisseria sp., Haemophilus influenzae , and most genera of the Enterobacteriaceae for 8 hours (for Enterobacter sp., the 8-hour serum levels exceed the MIC for 80% of strains). For Pseudomonas aeruginosa , a single 2 g intravenous dose produces serum levels that exceed the MIC 90 for approximately 4 to 6 hours. All of the above doses of AZACTAM result in average urine levels of aztreonam that exceed the MIC 90 for the same pathogens for up to 12 hours. When aztreonam pharmacokinetics were assessed for adult and pediatric patients, they were found to be comparable (down to 9 months old). The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration. In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume. In elderly patients, the mean serum half-life of aztreonam increased and the renal clearance decreased, consistent with the age-related decrease in creatinine clearance. The dosage of AZACTAM should be adjusted accordingly (see ). In patients with impaired renal function, the serum half-life of aztreonam is prolonged. (See .) The serum half-life of aztreonam is only slightly prolonged in patients with hepatic impairment since the liver is a minor pathway of excretion. Average urine concentrations of aztreonam were approximately 1100 mcg/mL, 3500 mcg/mL, and 6600 mcg/mL within the first 2 hours following single 500 mg, 1 g, and 2 g intravenous doses of AZACTAM (30-minute infusions), respectively. The range of average concentrations for aztreonam in the 8- to 12-hour urine specimens in these studies was 25 to 120 mcg/mL. After intramuscular injection of single 500 mg and 1
the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicateduncomplicated)including pyelonephritis+9 more
1986
30
BARACLUDE
entecavir
LOE Approaching
ORAL · SOLUTION
12.1 Mechanism of Action Entecavir is an antiviral drug against hepatitis B virus [see ]. 12.3 Pharmacokinetics The single- and multiple-dose pharmacokinetics of entecavir were evaluated in healthy subjects and subjects with chronic hepatitis B virus infection. Absorption Following oral administration in healthy subjects, entecavir peak plasma concentrations occurred between 0.5 and 1.5 hours. Following multiple daily doses ranging from 0.1 to 1 mg, C max and area under the concentration-time curve (AUC) at steady state increased in proportion to dose. Steady state was achieved after 6 to 10 days of once-daily administration with approximately 2-fold accumulation. For a 0.5 mg oral dose, C max at steady state was 4.2 ng/mL and trough plasma concentration (C trough ) was 0.3 ng/mL. For a 1 mg oral dose, C max was 8.2 ng/mL and C trough was 0.5 ng/mL. In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution. The oral solution and tablet may be used interchangeably. Effects of food on oral absorption: Oral administration of 0.5 mg of entecavir with a standard high-fat meal (945 kcal, 54.6 g fat) or a light meal (379 kcal, 8.2 g fat) resulted in a delay in absorption (1.0–1.5 hours fed vs. 0.75 hours fasted), a decrease in C max of 44%–46%, and a decrease in AUC of 18%–20% [see ]. Distribution Based on the pharmacokinetic profile of entecavir after oral dosing, the estimated apparent volume of distribution is in excess of total body water, suggesting that entecavir is extensively distributed into tissues. Binding of entecavir to human serum proteins in vitro was approximately 13%. Metabolism and Elimination Following administration of C-entecavir in humans and rats, no oxidative or acetylated metabolites were observed. Minor amounts of phase II metabolites (glucuronide and sulfate conjugates) were observed. Entecavir is not a substrate, inhibitor, or inducer of the cytochrome P450 (CYP450) enzyme system. See , below. After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours. The observed drug accumulation index is approximately 2-fold with once-daily dosing, suggesting an effective accumulation half-life of approximately 24 hours. Entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged drug at steady state ranging from 62% to 73% of the administered dose. Renal clearance is independent of dose and ranges from 360 to 471 mL/min suggesting that entecavir undergoes both glomerular filtration and net tubular secretion [see ]. Special Populations Gender : There are no significant gender differences in entecavir pharmacokinetics. Race : There are no significant racial differences in entecavir pharmacokinetics. Elderly : The effect of age on the pharmacokinetics of entecavir was evaluated following administration of a single 1 mg oral dose in healthy young and elderly volunteer
chronic hepatitis B virus infection in adultsolder with evidence of active viral replicationeither evidence of persistent elevations in serum aminotransferases (ALT+4 more
2005
30
BARACLUDE
entecavir
LOE Approaching
ORAL · TABLET
12.1 Mechanism of Action Entecavir is an antiviral drug against hepatitis B virus [see ]. 12.3 Pharmacokinetics The single- and multiple-dose pharmacokinetics of entecavir were evaluated in healthy subjects and subjects with chronic hepatitis B virus infection. Absorption Following oral administration in healthy subjects, entecavir peak plasma concentrations occurred between 0.5 and 1.5 hours. Following multiple daily doses ranging from 0.1 to 1 mg, C max and area under the concentration-time curve (AUC) at steady state increased in proportion to dose. Steady state was achieved after 6 to 10 days of once-daily administration with approximately 2-fold accumulation. For a 0.5 mg oral dose, C max at steady state was 4.2 ng/mL and trough plasma concentration (C trough ) was 0.3 ng/mL. For a 1 mg oral dose, C max was 8.2 ng/mL and C trough was 0.5 ng/mL. In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution. The oral solution and tablet may be used interchangeably. Effects of food on oral absorption: Oral administration of 0.5 mg of entecavir with a standard high-fat meal (945 kcal, 54.6 g fat) or a light meal (379 kcal, 8.2 g fat) resulted in a delay in absorption (1.0–1.5 hours fed vs. 0.75 hours fasted), a decrease in C max of 44%–46%, and a decrease in AUC of 18%–20% [see ]. Distribution Based on the pharmacokinetic profile of entecavir after oral dosing, the estimated apparent volume of distribution is in excess of total body water, suggesting that entecavir is extensively distributed into tissues. Binding of entecavir to human serum proteins in vitro was approximately 13%. Metabolism and Elimination Following administration of C-entecavir in humans and rats, no oxidative or acetylated metabolites were observed. Minor amounts of phase II metabolites (glucuronide and sulfate conjugates) were observed. Entecavir is not a substrate, inhibitor, or inducer of the cytochrome P450 (CYP450) enzyme system. See , below. After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours. The observed drug accumulation index is approximately 2-fold with once-daily dosing, suggesting an effective accumulation half-life of approximately 24 hours. Entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged drug at steady state ranging from 62% to 73% of the administered dose. Renal clearance is independent of dose and ranges from 360 to 471 mL/min suggesting that entecavir undergoes both glomerular filtration and net tubular secretion [see ]. Special Populations Gender : There are no significant gender differences in entecavir pharmacokinetics. Race : There are no significant racial differences in entecavir pharmacokinetics. Elderly : The effect of age on the pharmacokinetics of entecavir was evaluated following administration of a single 1 mg oral dose in healthy young and elderly volunteer
chronic hepatitis B virus infection in adultsolder with evidence of active viral replicationeither evidence of persistent elevations in serum aminotransferases (ALT+4 more
2005
30
CAMZYOS
mavacamten
Peak
ORAL · CAPSULE
Cardiac Myosin Inhibitors
symptoms
2022
0

Pipeline & Clinical Trials

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanes
Hepatitis C
N/A
Clinical Trials (1)
NCT03071133Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
N/A
N/A
Clinical Trials (1)
NCT02475382Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
N/A
not applicable
Ischemic Stroke
N/A
Non-Interventional
Hepatitis C
N/A
Clinical Trials (5)
NCT03205618A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar
N/A
NCT01394666Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
N/A
NCT03595891The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
N/A

+2 more

Enhanced Clinical Intervention
Bipolar Disorder
N/A
Asunaprevir
Hepatitis C
N/A
Clinical Trials (5)
NCT02580474The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Phase 4
NCT02170727A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
Phase 3
NCT01718145A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Phase 3

+2 more

BMS-986094/INX-08189
Healthy
N/A
Clinical Trials (1)
NCT01732848A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
N/A
Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
Non-Small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT02910999Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
N/A
N/A
Clinical Trials (1)
NCT01496417Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores
N/A
Blood test: genotype testing
HIV Infection
N/A
ORENCIA Subcutaneous Injection
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT02758769Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings
N/A
A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients
Hepatitis C
N/A
Clinical Trials (1)
NCT01594554A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.
N/A
Safety Study of Abatacept to Treat Rheumatoid Arthritis
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT01247766Safety Study of Abatacept to Treat Rheumatoid Arthritis
N/A
N/A
Clinical Trials (1)
NCT00706641Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
N/A
Nivolumab + Relatlimab
Advanced Melanoma
N/A
Clinical Trials (1)
NCT07079644Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
N/A
Non-Interventional
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT03274141Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)
N/A
A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT03457792A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis
N/A
Lisocabtagene maraleucel
Chronic Lymphocytic Leukemia (CLL)
N/A
Clinical Trials (5)
NCT03744676A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Phase 2
NCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
N/A
NCT06357754Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
N/A

+2 more

A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT03188081A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept
N/A
Apixaban in Atrial Fibrillation Registry
Atrial Fibrillation
N/A
Clinical Trials (1)
NCT02563639Apixaban in Atrial Fibrillation Registry
N/A
Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT01137851Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
N/A
Atazanavir
HIV Infections
N/A
Clinical Trials (5)
NCT00447070Effect of Atazanavir on Endothelial Function in HIV-Infected Patients
Phase 4
NCT00207142Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
Phase 4
NCT00312754A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
Phase 4

+2 more

N/A
Clinical Trials (5)
NCT02295475Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
Phase 4
NCT02942407Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
Phase 4
NCT00839657Clarification of Optimal Anticoagulation Through Genetics
Phase 3

+2 more

Safety Study of Abatacept in Sweden
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT01094795Safety Study of Abatacept in Sweden
N/A
Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir
HIV/AIDS
N/A
Clinical Trials (1)
NCT02532673Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir
N/A
Ipilimumab
Melanoma
N/A
Clinical Trials (1)
NCT00495066Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
N/A
Non-Interventional
Lung Cancer
N/A
Clinical Trials (1)
NCT03382496Observational Study for Lung Cancer Patients Treated With Nivolumab
N/A
N/A
Clinical Trials (1)
NCT00209027The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
N/A
Non-interventional
Hepatitis C
N/A
Clinical Trials (1)
NCT03366610Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens
N/A
N/A
Clinical Trials (1)
NCT07383025Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
N/A
N/A
Clinical Trials (1)
NCT00002207A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients
N/A
Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain
Pain
N/A
Clinical Trials (1)
NCT02651363Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain
N/A
LPV/RTV + 2NRTIs
HIV Infection
N/A
Clinical Trials (1)
NCT00096746Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
N/A
Integrated Behavioral Care
Type 2 Diabetes Mellitus
N/A
Clinical Trials (1)
NCT02863523COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes
N/A
N/A
Clinical Trials (5)
NCT06188637Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study
Phase 4
NCT06396039A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
Phase 4
NCT05369832An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
Phase 4

+2 more

Non-Interventional
Renal Cell Carcinoma
N/A
Clinical Trials (1)
NCT03663946A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
N/A
The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
HIV Positive
N/A
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, a
Alzheimer Disease
N/A
Clinical Trials (1)
NCT01348061Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
N/A
Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Tre
Diabetes Mellitus, Type 2
N/A
A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That
Renal Cell Carcinoma
N/A
Clinical Trials (1)
NCT03161145A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread
N/A
¹³C-Methacetin Breath Test
NASH - Nonalcoholic Steatohepatitis
N/A
Clinical Trials (1)
NCT03611101Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
N/A
N/A
Clinical Trials (1)
NCT06361576Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
N/A
Blood draw
Atherosclerosis
N/A
Clinical Trials (1)
NCT00847782An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
N/A
Didanosine
HIV Infections
N/A
Clinical Trials (5)
NCT00000637A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
Phase 3
NCT00000823A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
Phase 2
NCT00000770A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
Phase 2

+2 more

Hydroxyurea
HIV Infections
N/A
Clinical Trials (1)
NCT00002176A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
N/A
N/A
Clinical Trials (1)
NCT00223418Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
N/A
Non-Interventional
Melanoma
N/A
Clinical Trials (1)
NCT03696069A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
N/A
Non-Interventional
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT03696173Safety Study of Abatacept in Rheumatoid Arthritis Participants
N/A
Nivolumab and Ipilimumab
Cervix Cancer
N/A
Clinical Trials (1)
NCT04256213COL Immunotherapy Before Radiochimio + Ipilimumab
N/A
metreleptin
Lipodystrophy
N/A
Clinical Trials (1)
NCT00677313An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
N/A

Open Jobs (731)

Senior Therapeutic Area Specialist, Cardiovascular Specialty - Bowling Green, KY

Field - United States - US
23h ago
$134K - $163K/yr

Cardiovascular TAS

Field - Colombia - CO
23h ago

Executive Director, Early Differentiation & Pipeline, Global Medical Neuroscience

Princeton - NJ - US
23h ago
$255K - $308K/yr

Scientist, Analytical Development

New Brunswick - NJ - US
23h ago
$99K - $120K/yr

Principal Scientist, Cardiovascular Translational Biomarker

Princeton - NJ - US
23h ago
$136K - $165K/yr

Senior Director, Policy Communications

Washington DC - US
23h ago
$225K - $273K/yr

VP Finance, Research

Princeton - NJ - US
23h ago
$274K - $333K/yr

Senior Director, CTDO Finance Business Parter

New Brunswick - NJ - US
23h ago
$223K - $270K/yr

Associate Director, Commercial AI Product Owner

Princeton - NJ - US
23h ago
$168K - $203K/yr

Senior Therapeutic Area Specialist, Oncology- Indianapolis South, IN

Indianapolis - IN - US
23h ago
$145K - $175K/yr

Sr. Specialist, Workforce Administration

Hyderabad - TS - IN
23h ago

Senior Principal Scientist, Cardiovascular, Translational Development

Princeton - NJ - US
23h ago
$184K - $223K/yr

Associate Director, Operational Excellence, Cell Therapy in Devens, MA

Devens - MA - US
23h ago
$179K - $217K/yr

Associate Research Scientist

San Diego - CA - US
23h ago
$91K - $111K/yr

Executive Director - Operational Risk Assessment & Oversight

Princeton - NJ - US
23h ago
$276K - $335K/yr

Senior Therapeutic Area Specialist, Cardiovascular Specialty - Boston, MA

Boston - MA - US
23h ago
$134K - $163K/yr

Business Analyst, R&D Portfolio Operations Business Insights & Technology (BI&T)

Princeton - NJ - US
23h ago
$108K - $131K/yr

Manager, Parenteral Manufacturing - Isolation Technology

Manati - PR - US
23h ago
$78K - $94K/yr

Sr. Manager, Sr. Manager, Sotyktu PSO/PSA & Orencia

Princeton - NJ - US
23h ago
$134K - $162K/yr

Director, Network Orchestrator

Madison - Giralda - NJ - US
23h ago
$193K - $234K/yr

Manager, International Patient Safety - Poland Hub

Warsaw - PL
23h ago

Manager, International Patient Safety - Poland Hub

Warsaw - PL
23h ago

Manager, International Patient Safety - Poland Hub

Warsaw - PL
23h ago

Analyst, US Commercialization Decision Intelligence & KDA Solutions

Hyderabad - TS - IN
23h ago

Analyst, Perception Analytics

Hyderabad - TS - IN
23h ago
View all 731 open positions →
Interview Prep Quick Facts
Portfolio: 387 approved products, 167 clinical trials
Top TAs: Oncology, Infectious Diseases, Immunology
H-1B (2023): 1 approval
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 731 active jobs
Portfolio Health
Pre-Launch176 (45%)
Launch2 (1%)
Growth4 (1%)
Peak20 (5%)
LOE Approaching83 (21%)
Post-LOE102 (26%)
387 total products
Therapeutic Area Focus
Oncology
20 marketed2025 pipeline
Infectious Diseases
15 marketed332 pipeline
Immunology
7 marketed248 pipeline
Cardiovascular
11 marketed173 pipeline
Metabolic Diseases
5 marketed129 pipeline
Neurology
8 marketed123 pipeline
Nephrology
50 pipeline
Hematology
3 marketed44 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$45.0B2%
R&D Spend
$9.3B(21%)2%
Net Income
$8.0B
Cash
$10.3B
Source: SEC 10-K Filing

Hiring Trend

Actively Hiring
731
Open Roles
+748
Added
-57
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub